AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10593621 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater social network contacts
Number of subjects: 671
Study 10593621 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower social participation
Number of subjects: 671
Study 10593621 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 671
Study 10593621 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-affective depressive symptoms in placebo-treated patients
Number of subjects: 671
Study 8739113 — intervention group
Group type: EXPERIMENTAL
Intervention: m‐chlorophenylpiperazine (m‐CPP)
Number of subjects: 12
Study 8739113 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐tryptophan (L‐TRP)
Number of subjects: 12
Study 8739113 — intervention group
Group type: EXPERIMENTAL
Intervention: m‐CPP
Number of subjects: 12
Study 8739113 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐TRP
Number of subjects: 12
Study 1948293 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewer assessment using the Disability Assessment Schedule (DAS II)
Number of subjects: 30
Study 1948293 — intervention group
Group type: COMPARATOR
Intervention: Observer assessment using the Disability Assessment Schedule (DAS II)
Number of subjects: 30
Study 1948293 — intervention group
Group type: EXPERIMENTAL
Intervention: Items related to social and cultural expectations on 'normal behaviour'
Number of subjects: 30
Study 1948293 — intervention group
Group type: EXPERIMENTAL
Intervention: Section 3 of the DAS
Number of subjects: 30
Study 7034758 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine in 8% dextrose, 2 ml, 3 ml, or 4 ml
Number of subjects: 57
Study 7034758 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine in 8% dextrose, 1.3 ml or 2 ml
Number of subjects: 57
Study 7034758 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine in 8% dextrose, 3 ml
Number of subjects: 57
Study 7034758 — intervention group
Group type: EXPERIMENTAL
Intervention: Both solutions (0.5% and 0.75%)
Number of subjects: 57
Study 7034758 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine
Number of subjects: 57
Study 31544376 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm acupuncture
Number of subjects: 90
Study 31544376 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 90
Study 31544376 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 90
Study 29071848 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinye Baidu Granule
Number of subjects: 623
Study 29071848 — intervention group
Group type: COMPARATOR
Intervention: Fufang Shuanghua granule
Number of subjects: 623
Study 27057798 — intervention group
Group type: EXPERIMENTAL
Intervention: Proliposomal 4% ropivacaine
Number of subjects: 15
Study 27057798 — intervention group
Group type: COMPARATOR
Intervention: Plain 0.5% ropivacaine
Number of subjects: 15
Study 25136017 — intervention group
Group type: EXPERIMENTAL
Intervention: KAF156 single dose (10 to 1,200 mg)
Number of subjects: 70
Study 25136017 — intervention group
Group type: EXPERIMENTAL
Intervention: KAF156 multiple doses (60 to 600 mg once daily for 3 days)
Number of subjects: 70
Study 25136017 — intervention group
Group type: COMPARATOR
Intervention: KAF156 (400 mg) under fed conditions
Number of subjects: 70
Study 25136017 — intervention group
Group type: EXPERIMENTAL
Intervention: KAF156 (single and multiple doses)
Number of subjects: 70
Study 22311907 — intervention group
Group type: COMPARATOR
Intervention: sFlt1 levels at 20 weeks' gestation
Number of subjects: 109
Study 22311907 — intervention group
Group type: COMPARATOR
Intervention: sFlt1:placental growth factor ratio at 20 weeks' gestation
Number of subjects: 109
Study 22311907 — intervention group
Group type: COMPARATOR
Intervention: sFlt1, soluble endoglin, and sFlt1:placental growth factor ratio at clinical diagnosis
Number of subjects: 109
Study 22311907 — intervention group
Group type: COMPARATOR
Intervention: Placental growth factor levels at clinical diagnosis
Number of subjects: 109
Study 20633284 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (200 mg/kg/dose, 3 doses at 0, 12, and 36 hours)
Number of subjects: 20
Study 20633284 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 17438344 — intervention group
Group type: EXPERIMENTAL
Intervention: Utrecht Coping Power Program (UCPP)
Number of subjects: 77
Study 17438344 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (family therapy or behavior therapy)
Number of subjects: 77
Study 15677866 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5.87 mg/day, SD = 1.92)
Number of subjects: 147
Study 15677866 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (14.81 mg/day, SD = 6.25)
Number of subjects: 147
Study 15677866 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (6.41 mg/day, SD = 1.82)
Number of subjects: 147
Study 15677866 — intervention group
Group type: COMPARATOR
Intervention: Historical untreated group (1991-1996)
Number of subjects: 147
Study 12797647 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 10 mg once a day for 4 weeks
Number of subjects: 0
Study 9583851 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose lipid (25-30% of total daily energy)
Number of subjects: 512
Study 9583851 — intervention group
Group type: COMPARATOR
Intervention: Low dose lipid (6-8% of total daily energy)
Number of subjects: 512
Study 10327712 — intervention group
Group type: EXPERIMENTAL
Intervention: Spraying
Number of subjects: 0
Study 10327712 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing improvement
Number of subjects: 0
Study 10327712 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of spraying plus housing improvement
Number of subjects: 0
Study 10327712 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study 1906102 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (HFJV)
Number of subjects: 144
Study 1906102 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CV)
Number of subjects: 144
Study 1906102 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover from CV to HFJV
Number of subjects: 144
Study 1906102 — intervention group
Group type: COMPARATOR
Intervention: Crossover from HFJV to CV
Number of subjects: 144
Study 1906102 — intervention group
Group type: EXPERIMENTAL
Intervention: HFJV
Number of subjects: 144
Study 1906102 — intervention group
Group type: COMPARATOR
Intervention: CV
Number of subjects: 144
Study 1906102 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 144
Study 6337038 — intervention group
Group type: EXPERIMENTAL
Intervention: heparin 5000
Number of subjects: 660
Study 6337038 — intervention group
Group type: EXPERIMENTAL
Intervention: heparin 2500
Number of subjects: 660
Study 6337038 — intervention group
Group type: EXPERIMENTAL
Intervention: heparin 2500 and 0.5 mg dihydroergotamine (HDHE 2500)
Number of subjects: 660
Study 6337038 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg dihydroergotamine (DHE)
Number of subjects: 660
Study 6337038 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 660
Study 6337038 — intervention group
Group type: EXPERIMENTAL
Intervention: DHE
Number of subjects: 660
Study 6337038 — intervention group
Group type: EXPERIMENTAL
Intervention: HDHE 2500
Number of subjects: 660
Study 30720339 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement collaborative intervention including interactive learning sessions, webinars, quality improvement coaching, and root cause analyses.
Number of subjects: 31
Study 30720339 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement collaborative targeting diagnostic errors of elevated blood pressure, adolescent depression, and abnormal laboratory studies.
Number of subjects: 31
Study 30720339 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement collaborative aimed at reducing diagnostic errors.
Number of subjects: 31
Study 29889294 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithelium-off corneal cross-linking (CXL)
Number of subjects: 93
Study 25595934 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX/FOLFOX
Number of subjects: 0
Study 25595934 — intervention group
Group type: COMPARATOR
Intervention: LV/5‐FU
Number of subjects: 0
Study 23985432 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH/SRD diet (target sodium, 50 mmol/2100 kcal) for 21 days
Number of subjects: 13
Study 21985226 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical coordination training (PCT)
Number of subjects: 294
Study 21985226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural theory‐based training (CBTr)
Number of subjects: 294
Study 21985226 — intervention group
Group type: COMPARATOR
Intervention: Reference group (REF)
Number of subjects: 294
Study 19225130 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy intake and isoflavones
Number of subjects: 250
Study 19225130 — intervention group
Group type: EXPERIMENTAL
Intervention: Equol hypothesis
Number of subjects: 250
Study 19225130 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy intake
Number of subjects: 250
Study 16520153 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR)
Number of subjects: 2000
Study 16520153 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 2000
Study 15193477 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg daily from the day of embryo transfer until pregnancy test
Number of subjects: 1380
Study 15193477 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 1380
Study 10994153 — intervention group
Group type: EXPERIMENTAL
Intervention: myrtol standardized (4 x 300 mg, day 1‐14)
Number of subjects: 676
Study 10994153 — intervention group
Group type: EXPERIMENTAL
Intervention: cefuroxime (2 x 250 mg daily for day 1‐6)
Number of subjects: 676
Study 10994153 — intervention group
Group type: EXPERIMENTAL
Intervention: ambroxol (3 x 30 mg for day 1‐3, 2 x 30 mg for days 4‐14)
Number of subjects: 676
Study 10994153 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 676
Study 8635931 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-10 Neutron Gy (NGy) plus 38 Photon Gy (PhGy)
Number of subjects: 151
Study 8635931 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 Neutron Gy (NGy) plus 18 Photon Gy (PhGy)
Number of subjects: 151
Study 8635931 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-10 Neutron Gy (NGy)
Number of subjects: 151
Study 8635931 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 Neutron Gy (NGy)
Number of subjects: 151
Study 8635931 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 151
Study 8635931 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with initial PSA ≤ 10
Number of subjects: 151
Study 1352521 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine
Number of subjects: 0
Study 1352521 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 6428905 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate
Number of subjects: 16
Study 6428905 — intervention group
Group type: EXPERIMENTAL
Intervention: fenofibrate
Number of subjects: 16
Study 29564806 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated cross-linking (5 min of continuous UVA irradiation at 18 mW/cm2)
Number of subjects: 34
Study 29564806 — intervention group
Group type: COMPARATOR
Intervention: Conventional riboflavin-UVA-induced CXL (30 min of UVA irradiation at 3 mW/cm2)
Number of subjects: 34
Study 29564806 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Accelerated and Conventional CXL)
Number of subjects: 34
Study 29564806 — intervention group
Group type: COMPARATOR
Intervention: Conventional CXL
Number of subjects: 34
Study 30210070 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip (MC) treatment
Number of subjects: 3253
Study 26520434 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible cystoscopy
Number of subjects: 104
Study 26520434 — intervention group
Group type: COMPARATOR
Intervention: Rigid cystoscopy
Number of subjects: 104
Study 24343788 — intervention group
Group type: EXPERIMENTAL
Intervention: Operated knees (after arthroscopic surgery)
Number of subjects: 8
Study 24343788 — intervention group
Group type: COMPARATOR
Intervention: Control knees (asymptomatic non-operated contralateral knees)
Number of subjects: 8
Study 24343788 — intervention group
Group type: EXPERIMENTAL
Intervention: Operated knees (T2 values of suprapatellar subcutaneous adipose tissue)
Number of subjects: 8
Study 24343788 — intervention group
Group type: COMPARATOR
Intervention: Control knees (T2 values of suprapatellar subcutaneous adipose tissue)
Number of subjects: 8
Study 24343788 — intervention group
Group type: EXPERIMENTAL
Intervention: Operated knees (T2 values of deep intermuscular adipose tissue)
Number of subjects: 8
Study 24343788 — intervention group
Group type: COMPARATOR
Intervention: Control knees (T2 values of deep intermuscular adipose tissue)
Number of subjects: 8
Study 24343788 — intervention group
Group type: EXPERIMENTAL
Intervention: IFP T2 values ≤ 139 ms
Number of subjects: 8
Study 22732113 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided double-lumen tracheal tube (DLT)
Number of subjects: 50
Study 22732113 — intervention group
Group type: COMPARATOR
Intervention: Single-lumen tracheal tube with Arndt® blocker
Number of subjects: 50
Study 20847061 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption with same-sex partners
Number of subjects: 66
Study 20847061 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption with other-sex partners
Number of subjects: 66
Study 20847061 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (general)
Number of subjects: 66
Study 20847061 — intervention group
Group type: COMPARATOR
Intervention: No alcohol consumption (control)
Number of subjects: 66
Study 17585665 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at cervical Jiaji (EX‐B 2), 20 min each session, once a day, 10 sessions per course.
Number of subjects: 90
Study 17585665 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbs with modified Buzhong Yiqi Decoction, one dose each day, 10 doses per course.
Number of subjects: 90
Study 17585665 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine with bandazol, Dextran 40, Danshen tablet, and vitamin B12, 10 days per course.
Number of subjects: 90
Study 16271221 — intervention group
Group type: EXPERIMENTAL
Intervention: low level C(2)
Number of subjects: 53
Study 16271221 — intervention group
Group type: EXPERIMENTAL
Intervention: high level C(2)
Number of subjects: 53
Study 16271221 — intervention group
Group type: COMPARATOR
Intervention: C(0)
Number of subjects: 53
Study 12167139 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline alone (group 1)
Number of subjects: 39
Study 12167139 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline combined with fluoxetine (group 2)
Number of subjects: 39
Study 12167139 — intervention group
Group type: COMPARATOR
Intervention: Comparison of final headache index between groups
Number of subjects: 39
Study 10209075 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril, 20 mg/day (n=20)
Number of subjects: 40
Study 10209075 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 40
Study 9456943 — intervention group
Group type: COMPARATOR
Intervention: Manual injection at 2 ml/sec (Group 1)
Number of subjects: 50
Study 9456943 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic injection at 2 ml/sec (Group 3)
Number of subjects: 50
Study 9456943 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic injection at 4 ml/sec (Group 4)
Number of subjects: 50
Study 9456943 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic injection at 6 ml/sec (Group 5)
Number of subjects: 50
Study 9456943 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall evaluation of large and small diameter vessels
Number of subjects: 50
Study 9456943 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 50
Study 2143045 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (0.5 mg)
Number of subjects: 9
Study 2143045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 334082 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine hydrochloride
Number of subjects: 8
Study 334082 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine maleate
Number of subjects: 8
Study 334082 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 8
Study 31141198 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of two implants supporting a locator-retained mandibular overdenture
Number of subjects: 30
Study 31141198 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading of two implants supporting a locator-retained mandibular overdenture
Number of subjects: 30
Study 31141198 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (immediate and delayed loading)
Number of subjects: 30
Study 30802391 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hepatitis associated with pulmonary tuberculosis
Number of subjects: 1189
Study 30802391 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hepatitis C and B
Number of subjects: 1189
Study 30802391 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic steatohepatitis
Number of subjects: 1189
Study 30802391 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-alcoholic steatohepatitis
Number of subjects: 1189
Study 30802391 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal hepatitis
Number of subjects: 1189
Study 25832995 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose (0.6 mg/kg body weight; maximum 60 mg) i.v. rt-PA
Number of subjects: 2500
Study 25832995 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensive BP lowering (systolic target 130-140 mmHg)
Number of subjects: 2500
Study 25832995 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose (0.9 mg/kg body weight; maximum 90 mg) i.v. rt-PA
Number of subjects: 2500
Study 25832995 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended BP control (systolic target <180 mmHg)
Number of subjects: 2500
Study 23525080 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-viral, liposome-based gene therapy formulation
Number of subjects: 0
Study 23525080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21457152 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (0.5 mg.kg(‐1))
Number of subjects: 24
Study 21457152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19494179 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 847
Study 17110217 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.05 mg
Number of subjects: 416
Study 17110217 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.1 mg
Number of subjects: 416
Study 17110217 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg
Number of subjects: 416
Study 17110217 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 2.5 mg
Number of subjects: 416
Study 17110217 — intervention group
Group type: COMPARATOR
Intervention: Finasteride 5 mg
Number of subjects: 416
Study 17110217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 15017453 — intervention group
Group type: EXPERIMENTAL
Intervention: Concrete Objective Information (COI)
Number of subjects: 76
Study 15017453 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Instruction (RI)
Number of subjects: 76
Study 11316141 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg b.i.d.
Number of subjects: 537
Study 11316141 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg b.i.d.
Number of subjects: 537
Study 9135356 — intervention group
Group type: EXPERIMENTAL
Intervention: Scavenging system
Number of subjects: 40
Study 9135356 — intervention group
Group type: COMPARATOR
Intervention: No scavenging system
Number of subjects: 40
Study 8187254 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl
Number of subjects: 50
Study 8187254 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl
Number of subjects: 50
Study 8187254 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural route
Number of subjects: 50
Study 8187254 — intervention group
Group type: COMPARATOR
Intervention: Intravenous group
Number of subjects: 50
Study 3605278 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbal-based flap
Number of subjects: 20
Study 3605278 — intervention group
Group type: COMPARATOR
Intervention: Fornix-based flap
Number of subjects: 20
Study 30122896 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucostim® (5 μg/kg)
Number of subjects: 56
Study 30122896 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucostim® (10 μg/kg)
Number of subjects: 56
Study 30122896 — intervention group
Group type: COMPARATOR
Intervention: Neupogen® (5 μg/kg)
Number of subjects: 56
Study 30122896 — intervention group
Group type: COMPARATOR
Intervention: Neupogen® (10 μg/kg)
Number of subjects: 56
Study 30122896 — intervention group
Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 56
Study 27092674 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention (individual lifestyle counseling, group workshop, group counseling in healthy lifestyles, environmental intervention)
Number of subjects: 142
Study 27092674 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 142
Study 25531837 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical music during TRUS-guided prostate biopsy
Number of subjects: 76
Study 22607822 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 134537
Study 19840137 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQID hospitals (pay-for-performance program)
Number of subjects: 0
Study 19840137 — intervention group
Group type: COMPARATOR
Intervention: Non-PHQID hospitals (control group)
Number of subjects: 0
Study 18663723 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin 7.5/15 mg once daily (o.d.)
Number of subjects: 716
Study 15989122 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory responses after removing veridical responses
Number of subjects: 0
Study 15989122 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory blends for verbally quantified information
Number of subjects: 0